Neuren Pharmaceuticals (ASX:NEU) Total Assets : A$248.0 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Neuren Pharmaceuticals Total Assets?

Neuren Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was A$248.0 Mil.

During the past 12 months, Neuren Pharmaceuticals's average Total Assets Growth Rate was 529.40% per year. During the past 3 years, the average Total Assets Growth Rate was 194.00% per year. During the past 5 years, the average Total Assets Growth Rate was 57.00% per year. During the past 10 years, the average Total Assets Growth Rate was 18.10% per year.

During the past 13 years, Neuren Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 194.00%. The lowest was -61.30%. And the median was -20.20%.

Total Assets is connected with ROA %. Neuren Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was 126.52%. Total Assets is also linked to Revenue through Asset Turnover. Neuren Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.98.

Neuren Pharmaceuticals Total Assets Historical Data

The historical data trend for Neuren Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuren Pharmaceuticals Total Assets Chart

Neuren Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

14.41

24.95

40.06

43.27

247.97

Neuren Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial															40.06	34.59	43.27	97.52	247.97

Neuren Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Neuren Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	205.207	+	42.763
	=	248.0

Neuren Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	205.207	+	42.763
	=	248.0

Neuren Pharmaceuticals (ASX:NEU) Total Assets Explanation

Total Assets is connected with ROA %.

Neuren Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	218.552	/	( (97.523	+	247.97)	/ 2 )
	=	218.552	/	172.7465
	=	126.52 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Neuren Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	168.999	/	( (97.523	+	247.97)	/ 2 )
=	168.999	/	172.7465
=	0.98

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Neuren Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Neuren Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuren Pharmaceuticals (ASX:NEU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (ASX:NEU) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

NURPF:USA

Address

697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.neurenpharma.com

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.